Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

November 30, 2007

Conditions
HIV InfectionsDyslipidemiaHyperlipidemiaHypercholesterolemiaHypertriglyceridemia
Interventions
DRUG

Tenofovir disoproxil fumarate

Trial Locations (20)

10003

Beth Israel Medical Center, New York

19104

University of Pennsylvania, Philadelphia, Philadelphia

21201

University of Maryland, Institute of Human Virology, Baltimore

46202

Wishard Hospital, Indianapolis

92103

University of California, San Diego Antiviral Research Center, San Diego

90033-1079

University of Southern California, Los Angeles

80262-3706

University of Colorado Health Sciences Center, Denver, Denver

33136-1013

University of Miami, Miami

46202-5250

Indiana University Hospital, Indianapolis

Methodist Hospital of Indiana, Indianapolis

21287-8106

Johns Hopkins University, Baltimore

63108-2138

Washington University (St. Louis), St Louis

10016-6481

NYU/Bellevue, New York

Unknown

Duke University Medical Center, Durham

45267-0405

University of Cincinnati, Cincinnati

44106-5083

Case Western Reserve University, Cleveland

44109-1998

MetroHealth Medical Center, Cleveland

15213-2582

University of Pittsburgh, Pittsburgh

77555-0435

University of Texas, Galveston, Galveston

00936-5067

University of Puerto Rico, San Juan

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00109603 - Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy | Biotech Hunter | Biotech Hunter